Bristol-Myers Squibb Co (BMY) People | Reuters.com
Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

70.61USD
24 Jun 2016
Change (% chg)

$-2.03 (-2.79%)
Prev Close
$72.64
Open
$70.75
Day's High
$71.85
Day's Low
$70.53
Volume
7,414,129
Avg. Vol
6,075,354
52-wk High
$75.12
52-wk Low
$51.82

Summary

Name Age Since Current Position

Lamberto Andreotti

65 2015 Non-Executive Chairman of the Board

Giovanni Caforio

51 2015 Chief Executive Officer, Director

Charles Bancroft

56 2011 Chief Financial Officer, Executive Vice President

Louis Schmukler

60 2011 President - Global Manufacturing and Supply

Francis Cuss

61 2013 Executive Vice President, Chief Scientific Officer

Sandra Leung

55 2014 Executive Vice President, General Counsel and Corporate Secretary

Murdo Gordon

50 2016 Executive Vice President, Chief Commercial Officer

Paul von Autenried

54 2012 Senior Vice President - Enterprise Services, Chief Information Officer

Anne Nielsen

55 2013 Senior Vice President, Chief Compliance and Ethics Officer

Joseph Caldarella

60 2010 Senior Vice President, Corporate Controller

Ann Judge

50 2013 Senior Vice President - Global Human Resources

John Elicker

56 2012 Senior Vice President - Public Affairs

Togo West

73 2015 Lead Independent Director

Peter Arduini

51 2016 Independent Director

Laurie Glimcher

64 1997 Independent Director

Michael Grobstein

73 2007 Independent Director

Alan Lacy

62 2008 Independent Director

Thomas Lynch

55 2014 Independent Director

Dinesh Paliwal

58 2013 Independent Director

Vicki Sato

67 2006 Independent Director

Gerald Storch

59 2012 Independent Director

Biographies

Name Description

Lamberto Andreotti

Mr. Lamberto Andreotti is Non-Executive Chairman of the Board of Bristol-Myers Squibb Company effective as of May 5, 2015. He has served as Executive Chairman of the Board of the Company from May 5, 2015 to August 3, 2015. He is no longer Chief Executive Officer of the Company effective May 5, 2015. He was Chief Executive Officer, Director of Bristol-Myers Squibb Company. Mr. Andreotti has been Chief Executive Officer since May 2010. He was our President and Chief Operating Officer from March 2009 to May 2010. From March 2008 to March 2009, Mr. Andreotti served as Executive Vice President and Chief Operating Officer of BMS. From May 2007 until March 2008, he served as Executive Vice President of BMS and Chief Operating Officer of Worldwide Pharmaceuticals, a division of BMS. Mr. Andreotti served as Executive Vice President of BMS and President of Worldwide Pharmaceuticals from 2005-2007 and as Senior Vice President and International President of Worldwide Pharmaceuticals from 2002-2005. He is a member of Pharmaceutical Research and Manufacturers of America and The Business Council.

Giovanni Caforio

Dr. Giovanni Caforio M.D., is Chief Executive Officer, Director of Bristol-Myers Squibb Company effective May 5, 2015. He was Chief Executive Officer-Designate from January to May 2015, Chief Operating Officer from June 2014 to May 2015, and he served as Executive Vice President and Chief Commercial Officer from November 2013 to June 2014. From October 2011 to November 2013, he served as President, U.S. He held the position of Senior Vice President, Global Commercialization and Immunology from May 2010 to October 2011. Prior to that, he served as Senior Vice President, Oncology, U.S. and Global Commercialization from March 2009 to May 2010. From January 2007 to March 2009 he served as Senior Vice President, U.S. Oncology and from May 2004 to January 2007, he served as Senior Vice President, European Marketing and Brand Commercialization. Dr. Caforio is a member of the Board of Trustees of Capital Health Systems and the Pharmaceutical Research and Manufacturers of America.

Charles Bancroft

Mr. Charles A. Bancroft is Chief Financial Officer, Executive Vice President of Bristol-Myers Squibb Co. He has been appointed as Executive Vice President effective October 19, 2011. He joined Bristol-Myers Squibb in 1984 and has since held positions of increasing responsibility within the finance organization, including international assignments, senior leadership positions in the global pharmaceutical business and also with ConvaTec. He received a B.S. in Accounting from Drexel University, his M.B.A. in Finance from Temple University and is a certified public accountant.

Louis Schmukler

Mr. Louis S. Schmukler is President - Global Manufacturing and Supply of Bristol-Myers Squibb Company. From 2007 to 2009, he was Senior Vice President, Pharmaceutical Operating Unit, Wyeth and from 2009 to 2011 – Senior Vice President, Specialty/Biotechnology Operating Unit, Pfizer.

Francis Cuss

Dr. Francis M. Cuss is Executive Vice President, Chief Scientific Officer of Bristol-Myers Squibb Co. Dr. Cuss joined Bristol-Myers Squibb in 2003 as senior vice president, Drug Discovery, adding responsibility for Discovery Medicine and Clinical Pharmacology in May 2006. Under Dr. Cuss' leadership, Bristol-Myers Squibb has consistently been rated a research organization based on cycle time, success rates and costs, having increased discovery output while maintaining a flat operating budget. Dr. Cuss and his team integrated Adnexus, Medarex and ZymoGenetics into the research organization, and have driven innovation in the research operating model, processes and governance. Dr. Cuss became a member of the company's Senior Management Team in 2010. Prior to joining Bristol-Myers Squibb, Dr. Cuss spent 14 years at Schering-Plough and three years at Glaxo, holding positions of increasing responsibility in discovery, clinical research and medical affairs in both the U.S. and Europe. Prior to joining the pharmaceutical industry, Dr. Cuss was a practicing physician and held several academic appointments, including as adjunct associate professor at Jefferson Medical College at Thomas Jefferson University in Philadelphia. Dr. Cuss received his medical training in the U.K. and holds medical degrees from Cambridge University. He is also a Fellow of the Royal College of Physicians and of the Faculty of Pharmaceutical Medicine.

Sandra Leung

Ms. Sandra Leung is Executive Vice President, General Counsel and Corporate Secretary of Bristol-Myers Squibb Co. She joined Bristol-Myers Squibb in 1992 as a staff attorney in the litigation department. In 1996 she became assistant counsel and one year later, was named associate counsel. In 1999, Sandy was appointed to the position of counsel and corporate secretary, and in 2002 became corporate vice president. Four years later, Sandy was named acting general counsel in addition to her other duties, and in 2007, she was named to her current position as senior vice president and general counsel. Before joining the company, Sandy spent eight years as a prosecutor in the Manhattan District Attorney’s office and was one of New York City’s first Asian-American female prosecutors. During her time there, she was part of the original special victims unit. She earned her law degree from Boston College of Law and her bachelor’s degree from Tufts University.

Murdo Gordon

Mr. Murdo Gordon has been appointed as Executive Vice President and Chief Commercial Officer of the Company, effective June 21, 2016. Gordon joined Bristol-Myers Squibb in 1989 and spent the first 14 years at the company in Canada where he held positions of increasing responsibility in sales and marketing. Gordon moved into the company’s U.S. operations in 2003 where he held senior commercial leadership positions in cardiovascular, neuroscience and market access. He led strategy and commercial operations as senior vice president for U.S. oncology and immunoscience from 2011 to 2013, and served as president, U.S. from 2013 to 2015. Murdo is a member of the Board of Directors of RWJBarnabas Health and received a BSc in Cell and Molecular Biology from Concordia University, Montreal, and also attended the General Management Program, CEDEP at INSEAD, Fontainebleau, France.

Paul von Autenried

Mr. Paul von Autenried is Senior Vice President - Enterprise Services, Chief Information Officer of Bristol-Myers Squibb Co. From 2007 to 2011 he was Vice President and Chief Information Officer, 2011 to 2012 – Senior Vice President and Chief Information Officer.

Anne Nielsen

Ms. Anne Nielsen is Senior Vice President, Chief Compliance and Ethics Officer of the company., She plays a critical leadership role in integrating the company’s ethics and values throughout Bristol-Myers Squibb. Anne provides guidance to the Board of Directors, the Senior Management Team and the Compliance and Ethics Council on all matters related to compliance and ethics. “Compliance and ethics are core to the Bristol-Myers Squibb culture and critical in helping us achieve our mission of delivering innovative medicines to patients with serious disease,” says Anne. “My organization works to ensure the highest standards of ethics and personal integrity as a foundation for the important work we do across the globe.” Anne joined Bristol-Myers Squibb in 1998 and has held a variety of roles in the Law Department. Most recently served as Senior Vice President and Deputy General Counsel supporting Research and Development, Europe, China, Global Commercialization, Medical and Market Access. Previously, she was based in Brussels, Belgium and handled European regulatory and anti-trust legal issues for Bristol-Myers Squibb. Anne received her undergraduate degree in Political Science and Economics and a Master’s degree in Political Science from the University of Hawaii. She received her J.D. from Columbia Law School, and a diploma and Master’s Degree in European Law from the College of Bruges (Belgium).

Joseph Caldarella

Mr. Joseph C. Caldarella is Senior Vice President, Corporate Controller of Bristol-Myers Squibb Co. He was 2005 to 2010, Vice President and Corporate Controller. He was 1998 to 2005 - Vice President, Finance, Pharmaceutical Research Institute, a division of the Company.

Ann Judge

Ms. Ann Powell Judge is Senior Vice President - Global Human Resources of Bristol-Myers Squibb Co. Prior to joining Bristol-Myers Squibb, Ms. Judge was chief human resources officer at Shire Pharmaceuticals. Before Shire, Ms. Judge was corporate vice president, Human Resources, for the Pharmaceutical Division at Wyeth. During her tenure at Wyeth, Ms. Judge also held positions of responsibility for human resources in the commercial organization and in the global manufacturing unit. Previously, she spent 13 years at The Dow Chemical Company, where she worked internationally in a variety of human resources positions of increasing scope and responsibility, spending some time living and working in Germany and Switzerland. Ms. Judge has a bachelor’s degree in Psychology from the University of Iowa and a master’s degree in Industrial Relations from the University of Minnesota.

John Elicker

Mr. John E. Elicker is Senior Vice President - Public Affairs of Bristol-Myers Squibb Co. He served as 2000 to 2002 – Senior Director, Investor Relations, 2002 to 2010 –Vice President, Investor Relations, 2010 to 2012 – Senior Vice President, Investor Relations.

Togo West

Hon. Togo Dennis West, Jr., is Lead Independent Director of Bristol-Myers Squibb Company effective May 5 2015. He has been Chairman of TLI Leadership Group, a strategic consulting firm since 2006. From 2004 to 2014, he was Chairman of Noblis, Inc., a non-profit science and technology company, and a member of the Board of Trustees since 2001. He became Trustee Emeritus of Noblis in September 2014. From 2004 to 2006, Secretary West was the Chief Executive Officer of the Joint Center for Political and Economic Studies, a non-profit research and public policy institution. He served as Of Counsel to the Washington, D.C. based law firm of Covington & Burling from 2000 to 2004. Secretary West served as U.S. Secretary of Veterans Affairs from 1998 to 2000 and as U.S. Secretary of the Army from 1993 to 1997. He is a Director on the Board of MedStar Health and a Trustee on the Council on Foreign Relations.

Peter Arduini

Mr. Peter J. Arduini has been appointed as Independent Director of the company., effective April 1, 2016. He has been President and Chief Executive Officer of Integra LifeSciences Holdings Corporation, a global medical technology company, since January 2012 and currently serves as a member of Integra's Board of Directors. He served as President and Chief Operating Officer of Integra from November 2010 to January 2012. Before joining Integra, Mr. Arduini was Corporate Vice President and President of Medication Delivery, Baxter Healthcare, from 2005 to 2010. Prior to joining Baxter, Mr. Arduini worked for General Electric Healthcare, where he spent much of his 15 years in a variety of management roles for domestic and global businesses, culminating in leading the global functional imaging business. Mr. Arduini also serves on the Board of Directors of ADVAMED (the Advanced Medical Technology Association), the Board of Directors of MDIC (the Medical Device Innovation Consortium), and the Board of Directors of the National Italian American Foundation.

Laurie Glimcher

Dr. Laurie H. Glimcher, M.D., is Independent Director of Bristol-Myers Squibb Company. She has served as the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and the Cornell University Provost for Medical Affairs since January 2012. In February 2016, Dr. Glimcher was named the next President and Chief Executive Officer of the Dana-Farber Cancer Institute beginning in January 2017. Dr. Glimcher was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health and Professor of Medicine at Harvard Medical School from 1990 to December 2011. She is a Fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences USA, and a member of the Institutes of Medicine of the National Academy of Sciences. She is also a member and past President of the American Association of Immunologists. She was elected to the American Society of Clinical Investigation, the American Association of Physicians and the American Association for the Advancement of Science. Dr. Glimcher serves on the Board of Trustees of Cornell University, the Board of Overseers of Weill Cornell Medical College and the Memorial Sloan-Kettering Cancer Center Board of Overseers. Dr. Glimcher also serves on the Scientific Advisory Boards of Cancer Research Institute, Health Care Ventures, Inc. and American Asthma Foundation.

Michael Grobstein

Mr. Michael Grobstein is Independent Director of Bristol-Myers Squibb Company. He is a retired Vice Chairman of Ernst & Young LLP, an independent registered public accounting firm. Mr. Grobstein worked with Ernst & Young from 1964 to 1998, and was admitted as a partner in 1975. He served as a Vice Chairman-International Operations from 1993 to 1998, as Vice Chairman-Planning, Marketing and Industry Services from 1987 to 1993, and Vice Chairman-Accounting and Auditing Services from 1984 to 1987. He serves on the Board of Trustees and Executive Committee and is the Treasurer of the Central Park Conservancy. He also serves on the Board of Directors of the Peer Health Exchange, Inc.

Alan Lacy

Mr. Alan J. Lacy is Independent Director of Bristol-Myers Squibb Company. He is currently the Non-Executive Chairman of Dave & Buster's Entertainment Inc. and previously served as the Chairman and Chief Executive Officer of Sears, Roebuck and Co. and the Vice Chairman and Chief Executive Officer of its successor, Sears Holdings Corporation, from 2000 to 2005. Mr. Lacy also served as Vice Chairman of Sears Holdings Corporation from 2005 to 2006. More recently, Mr. Lacy served as Senior Advisor to Oak Hill Capital Partners, L.P., a private equity investment firm, from 2007 to 2014. He is Trustee of Fidelity Funds and the California Chapter of The Nature Conservancy. Mr. Lacy is a Director of the Center for Advanced Study in the Behavioral Sciences at Stanford University.

Thomas Lynch

Dr. Thomas J. Lynch, Jr., M.D., Ph.D., is Independent Director of the company since January 1 2014. He has served as Chairman and Chief Executive officer of Massachusetts General Physicians Organization since July 2015. He has also served as a member of the Massachusetts General Hospital Board since 2015. He served as the Director of Yale Cancer Center and was the Richard and Jonathan Sackler Professor of Internal Medicine, Yale Cancer Center, Yale School of Medicine from 2009 to 2015. He has also served as the Physician-in-Chief of Smilow Cancer Hospital, Yale-New Haven since 2009. Prior to 2009, he served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital. Dr. Lynch is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer. He also serves as a Director on the board of the Kenneth B. Schwartz Center for Compassionate Healthcare and is a member of the Scientific Advisory Board of Arvinas, Inc.

Dinesh Paliwal

Mr. Dinesh C. Paliwal Independent Director of Bristol-Myers Squibb Company. He has served as Executive Chairman, President and Chief Executive Officer of Harman International Industries, Inc., a company that designs, manufactures and markets a wide range of audio and information solutions for the automotive, consumer and professional markets, since July 2008. Mr. Paliwal has served as President and Chief Executive Officer of Harman since July 2007. Prior to joining Harman, Mr. Paliwal served as a member of the Group Executive Committee of ABB Ltd., a provider of industrial automation, power transmission systems and services, from January 2001 until June 2007. Mr. Paliwal also served as President of Global Markets and Technology of ABB Ltd. from January 2006 until June 2007, as Chairman and Chief Executive Officer of ABB North America from January 2004 until June 2007, and as President and Chief Executive Officer of ABB Automation Technologies Division from October 2002 to December 2005. Mr. Paliwal is a member of the CEO Business Roundtable.

Vicki Sato

Dr. Vicki L. Sato, Ph.D., is Independent Director of Bristol-Myers Squibb Company. She has served as a professor of management practice at the Harvard Business School since July 2005. From July 2005 to October 2014 she served as professor of the practice of molecular and cell biology at Harvard University. In 2005, Dr. Sato retired as President of Vertex Pharmaceuticals Incorporated, a global biotechnology company, where she was responsible for research and development, business and corporate development, commercial operations, legal, and finance. Dr. Sato also served as Chief Scientific Officer, Senior Vice President of Research and Development, and Chair of the Scientific Advisory Board at Vertex before being named President in 2000.

Gerald Storch

Mr. Gerald Leonard Storch is Independent Director of Bristol-Myers Squibb Company. He has served as Chief Executive Officer of Hudson's Bay Company since January 2015, a leading owner and operator of department stores including Saks Fifth Avenue, Lord & Taylor, Hudson's Bay Department Stores, Home Outfitters, Saks OFF 5th, Kaufhof, Inno, and the e-commerce business Gilt. From November 2013 to January 2014 he served as Chairman and Chief Executive Officer of Storch Advisors. He also served as Chairman of Toys"R"Us, Inc. from February 2006 to November 2013 and Chief Executive Officer of Toys"R"Us from February 2006 to May 2013. Prior to joining Toys"R"Us, Mr. Storch served as Vice Chairman of Target Corporation. He joined Target in 1993 as Senior Vice President of Strategy and served in roles of increasing seniority over the next 12 years. Prior to joining Target, Mr. Storch was a partner at McKinsey & Company. He is a director of Fanatics, Inc.